GLSI (Greenwich LifeSciences) Interest Expense: $0.00 Mil (TTM As of Mar. 2026)

What is Greenwich LifeSciences Interest Expense?

Greenwich LifeSciences GLSI -7.17% 33 Interest Expense is $0.00 Mil as of Mar. 2026. GuruFocus rates GLSI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Greenwich LifeSciences's interest expense for the three months ended in Mar. 2026 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Greenwich LifeSciences's Operating Income for the three months ended in Mar. 2026 was $ -5.73 Mil. Greenwich LifeSciences's Interest Expense for the three months ended in Mar. 2026 was $ 0.00 Mil. Greenwich LifeSciences has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Greenwich LifeSciences (NAS:GLSI) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Greenwich LifeSciences's Interest Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-5.73 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $0.00 Mil.

Greenwich LifeSciences's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Greenwich LifeSciences had no long-term debt ⁽¹⁾.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Greenwich LifeSciences Inc has no debt.

Greenwich LifeSciences Interest Expense Historical Data

* Premium members only.

The historical data trend for Greenwich LifeSciences's Interest Expense can be seen below:

Greenwich LifeSciences Interest Expense Chart

Greenwich LifeSciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

0.00

Greenwich LifeSciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

33GF Score

Greenwich LifeSciences Inc GLSI

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Greenwich LifeSciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of $0.00 Mil mean?

Greenwich LifeSciences (GLSI) has a Interest Expense of $0.00 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Greenwich LifeSciences and its competitors.

Is Greenwich LifeSciences' Interest Expense too high?

Greenwich LifeSciences' current Interest Expense is $0.00 Mil. Overall, Greenwich LifeSciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.

How does Greenwich LifeSciences' Interest Expense compare to SABS and SRZN?

Greenwich LifeSciences' Interest Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Greenwich LifeSciences and its competitors. Greenwich LifeSciences's current Interest Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Greenwich LifeSciences stock overvalued right now?

Greenwich LifeSciences (GLSI) has a current Interest Expense of $0.00 Mil. The current Interest Expense is $0.00 Mil. Greenwich LifeSciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Greenwich LifeSciences (GLSI), the current Interest Expense is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Greenwich LifeSciences Business Description

Industry Healthcare Biotechnology

Comparable Companies SABS SRZN ZNTL ELDN CNXU BCYC IFRX NMRA TRDA RNAC VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477

Website https://www.greenwichlifesciences.com

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

33GF Score

Get the complete analysis for GLSI

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.89

Price

View GLSI Analysis

See Interest Expense data for all stocks →